SEC Tracker
Get the app
ANGO · XBRL financial data

AngioDynamics financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ANGO's year ends in late May)

In thousands of dollarsNov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026Aug 31, 2026
Revenue from contracts with customers79,07375,18270,980*67,49172,84572,00480,158*75,71179,43378,42386,607*80,915
Cost of goods and services sold38,81139,32132,465*30,76732,93933,14737,940*33,85434,65036,94439,834*32,875
Gross profit40,26235,86138,515*36,72439,90638,85742,218*41,85744,78341,47946,773*48,040
Research and development8,6588,1896,724*6,2856,4346,9136,590*6,4177,7687,0848,178*7,979
General and administrative9,28910,57810,441*10,97510,39110,49010,236*12,55510,15110,71910,266*12,467
Total operating expenses53,382242,41452,964*49,82251,00048,83148,006*52,51350,90854,43056,968*55,342
Operating income (loss)(13,120)(199,896)(14,449)*(13,098)(11,094)(9,974)(5,788)*(10,656)(6,125)(12,951)(10,195)*(7,302)
Interest expense(534)(394)(567)*—————————
Other income (expense)(32)(238)(259)*(173)125,430(325)*(178)(128)4,967(735)*94
Income tax expense (benefit)16,430(12,004)(692)*133(110)(2)(60)*65(5)12370*(199)
Net income (loss)(29,048)(187,736)(13,449)*(12,798)(10,738)(4,407)(6,050)*(10,903)(6,350)(8,084)(11,405)*(7,097)
Earnings per share, basic USD per share(0.72)(4.67)(0.33)*(0.31)(0.26)(0.11)(0.15)*(0.26)(0.15)(0.19)—(0.17)
Earnings per share, diluted USD per share(0.72)(4.67)(0.33)*(0.31)(0.26)(0.11)(0.15)*(0.26)(0.15)(0.19)—(0.17)
Weighted average shares, basic thousands of shares40,21940,23440,430*40,65340,92240,85340,983*41,17441,54241,59641,792*42,022
Weighted average shares, diluted thousands of shares40,21940,23440,304*40,65340,92240,85340,983*41,17441,54241,59641,792*42,022

Balance sheet

CSV

Fiscal quarters (ANGO's year ends in late May)

In thousands of dollarsNov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026Aug 31, 2026
Cash and cash equivalents60,89678,45176,05655,00554,08944,76055,89338,76241,63837,81053,86433,973
Accounts receivable51,60349,47543,61039,56343,15843,46842,89042,64344,43445,55248,32544,905
Inventory64,25458,06860,61664,70065,91863,10562,00662,25565,56958,57852,43654,953
Prepaid and other current assets8,71510,91312,97113,32612,19515,4407,53512,9969,70813,6128,7699,172
Total current assets185,468196,907193,253172,594175,360172,273168,324156,656161,349155,552163,394143,003
Property and equipment, net42,55737,04035,66634,37732,97732,53032,30031,06630,52729,14227,09727,728
Right-of-use asset4,1043,8545,8045,3134,8034,2973,8503,4115,7245,4085,0534,920
Goodwill159,22600—————————
Total assets499,623324,842317,671293,628291,550285,415280,144265,642269,681260,678267,163241,933
Accounts payable37,65035,15237,75131,27234,74630,26533,29131,88235,39029,10531,51326,579
Accrued liabilities29,23730,96341,09834,10839,91936,94935,51827,65729,85332,30338,90928,811
Total current liabilities78,03785,87491,15576,69988,59577,97176,19768,28271,96366,06674,71759,689
Lease liability, non-current2,5682,3223,9393,4903,0302,5712,1061,7254,4784,1813,8603,635
Total liabilities98,397106,144112,08597,046104,78299,54597,17486,78793,34887,32196,33877,970
Accumulated deficit(194,019)(381,755)(395,204)(408,002)(418,740)(423,147)(429,197)(440,100)(446,450)(454,534)(465,939)(473,036)
Total stockholders' equity401,226218,698205,586196,582186,768185,870182,970178,855176,333173,357170,825163,963
Total liabilities and equity499,623324,842317,671293,628291,550285,415280,144265,642269,681260,678267,163241,933
Common shares outstanding (cover page) thousands of shares39,85540,05540,27740,63440,46640,60740,63441,20041,21741,31941,33242,054

Cash flows

CSV

Fiscal quarters (ANGO's year ends in late May)

In thousands of dollarsNov 30, 2023Feb 29, 2024May 31, 2024Aug 31, 2024Nov 30, 2024Feb 28, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026Aug 31, 2026
Net income (loss)(29,048)(187,736)(13,449)*(12,798)(10,738)(4,407)(6,050)*(10,903)(6,350)(8,084)(11,405)*(7,097)
Stock-based compensation1,877*2,612*1,896*3,2052,528*2,398*1,641*4,4702,891*2,684*3,915*4,502
Net cash from operating activities5,266*(12,526)*5,001*(18,253)2,473*(13,159)*18,811*(15,914)4,661*(3,110)*17,452*(15,330)
Purchases of property and equipment554*607*566*1,092797*1,798*777*731422*1,015*413*379
Net cash from investing activities(1,793)*29,404*(2,336)*(2,405)(1,961)*(3,189)*(2,623)*(1,551)(1,621)*(1,507)*(1,270)*(3,148)
Share repurchases0*0*0*5521,118*0*0*00*0*0*—
Proceeds from long-term debt0*0*——————————
Repayments of long-term debt0*0*0*00*0*0*———year only—
Net cash from financing activities(352)*694*(5,000)*(509)(1,123)*7,147*(5,770)*143(92)*621*(108)*(1,375)
Net change in cash3,310*17,555*(2,395)*(21,051)(916)*(9,329)*11,133*(17,131)2,876*(3,828)*16,054*(19,891)

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Angiodynamics33,97380,915(15,330)42.1M2.2 quarters 10-QAug 31, 2026
Orthofix Medical103,810210,933(6,224)*40.7M16.7 quarters 10-QJun 30, 2026
Axogen328,88875,83416,536*59.7M— 10-QSep 30, 2026
Delcath Systems47,52129,1335,712*34.7M— 10-QJun 30, 2026
Ceribell41,98929,341(13,078)*38.8M7.8 quarters 10-QSep 30, 2026
Iradimed63,28824,2036,997*12.8M— 10-QSep 30, 2026
Pulse Biosciences101,620434(18,709)*71.3M5.4 quarters 10-QJun 30, 2026
Butterfly Network122,30132,598(2,266)*not reported10.3 quarters 10-QSep 30, 2026
Orthopediatrics17,14172,6614,506*26.1M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.